Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by ronrydellon Apr 04, 2013 1:06pm

306 Views

Post# 21211272

RE: $109B + $102B = $211B

Gotta love your optimism NexVas...I'm glued to the etrade screen as well as stockhouse and continue to buy at 1000 share increments about every 30 minutes. Don't want to be caught having to buy at $6- like last Nov 10 2010 or in March of 2010 when we were getting one dollar a day increases occasionally.

It seems like everything is for real this time, BUT I'm prepared to place a stop limit when we're at $15 or so this summer, (presuming we get the "annoucement" we're all patiently waiting for) and protect against something resembling the fall of 2010.

This is going to be an exciting April, May and June!!!

Bullboard Posts

Changing Europe’s dependency on HREE from China